Ontario study finds med reviews lead to a reduction in fall-related fractures and an overall reduction in fall-related injuries in community-dwelling older adults.
The U.S. Food and Drug Administration recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community.